Evolus Logo Nov 2018.png
Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic Surgery
January 27, 2020 09:00 ET | Evolus
NEWPORT BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today...
Evolus Logo Nov 2018.png
Evolus Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue
January 09, 2020 09:00 ET | Evolus
Q4 2019 net revenue estimated between $18.5 and $19.5 million; increased from $13.2 million in Q3 2019 Completed Q4 2019 with over 3,500 purchasing accounts; increased from over 2,000 at end...
Evolus Logo Nov 2018.png
Evolus to Participate in Stifel Healthcare Conference
November 07, 2019 16:10 ET | Evolus
NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today...
Evolus Logo Nov 2018.png
Evolus Announces Pricing of Public Offering of Common Stock
November 07, 2019 01:18 ET | Evolus
NEWPORT BEACH, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public...
Evolus Logo Nov 2018.png
Evolus Announces Proposed Public Offering of Common Stock
November 06, 2019 16:02 ET | Evolus
NEWPORT BEACH, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and...
Evolus Logo Nov 2018.png
Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update
November 04, 2019 07:00 ET | Evolus
Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau® Achieved Number Three Unit...
Evolus Logo Nov 2018.png
Evolus to Report Third Quarter 2019 Financial Results and Provide a Business Update on Monday, November 4, 2019
October 28, 2019 16:05 ET | Evolus
NEWPORT BEACH, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,...
Evolus Logo Nov 2018.png
Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in Canada
October 16, 2019 09:05 ET | Evolus
NEWPORT BEACH, Calif. and CAMBRIDGE, Ontario, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) and Clarion Medical Technologies, a leading Canadian provider of medical and aesthetic...
Evolus Logo Nov 2018.png
Evolus Receives Approval for Nuceiva™ in the European Union
October 01, 2019 09:09 ET | Evolus
NEWPORT BEACH, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today...
Evolus Logo Nov 2018.png
Evolus will Participate in Cantor Global Healthcare Conference
September 18, 2019 09:00 ET | Evolus
NEWPORT BEACH, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,...